BioAge Labs (NASDAQ:BIOA) Raised to “Sell” at Wall Street Zen

BioAge Labs (NASDAQ:BIOA) was upgraded by equities research analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a research note issued to investors on Sunday, Wall Street Zen reports.

Several other equities analysts also recently issued reports on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, July 21st. Jefferies Financial Group set a $21.00 target price on shares of BioAge Labs in a research report on Friday, July 31st. Needham & Company LLC cut their price target on shares of BioAge Labs from $50.00 to $35.00 and set a “buy” rating on the stock in a research note on Friday, July 31st. Roth Capital reaffirmed a “buy” rating and issued a $25.00 price target on shares of BioAge Labs in a report on Wednesday, September 9th. Finally, BTIG Research reiterated a “buy” rating and set a $40.00 price objective on shares of BioAge Labs in a research note on Tuesday, September 8th. Six analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, BioAge Labs has an average rating of “Moderate Buy” and an average price target of $36.57.

BioAge Labs Price Performance

BioAge Labs stock opened at $8.48 on Friday. The stock has a market capitalization of $389.23 million, a price-to-earnings ratio of -3.56 and a beta of 0.94. BioAge Labs has a 1-year low of $4.68 and a 1-year high of $25.95. The business has a fifty day moving average price of $14.60 and a 200-day moving average price of $17.33.

BioAge Labs (NASDAQ:BIOA) last announced its earnings results on Wednesday, August 5th. The company reported ($0.58) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.65) by $0.07. The company had revenue of $2.45 million for the quarter. BioAge Labs had a negative return on equity of 28.99% and a negative net margin of 912.26%. On average, equities research analysts anticipate that BioAge Labs will post -2.45 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioAge Labs

A number of large investors have recently bought and sold shares of BIOA. Legal & General Group Plc acquired a new stake in BioAge Labs during the 2nd quarter valued at approximately $84,000. State of Wyoming acquired a new stake in shares of BioAge Labs in the second quarter worth $154,000. The Manufacturers Life Insurance Company purchased a new position in shares of BioAge Labs during the second quarter worth $234,000. Bank of Nova Scotia acquired a new position in BioAge Labs during the first quarter valued at $180,000. Finally, California State Teachers Retirement System lifted its position in BioAge Labs by 531.8% during the second quarter. California State Teachers Retirement System now owns 10,368 shares of the company’s stock valued at $254,000 after purchasing an additional 8,727 shares during the period.

About BioAge Labs

BioAge Labs, Inc (NASDAQ:BIOA) is a clinical-stage biotechnology company focused on developing medicines that target the biological mechanisms of aging. Its research uses human longevity data and proprietary computational biology tools to identify pathways associated with aging-related diseases and to develop potential therapies aimed at extending healthy lifespan and improving physical function.

The company’s lead investigational program is azelaprag, also known as BGE-105, an oral small-molecule apelin receptor agonist being studied for its potential to preserve muscle mass and improve physical performance in older adults.